METAvivor Research and Support Inc., a non-profit organization dedicated to funding research for Stage IV metastatic breast cancer (MBC), announces twelve grant awards totaling $1,650,000. These research grants will enhance the understanding of metastatic breast cancer, and help develop greatly needed therapeutic options to combat this complicated disease. Since its founding in 2009, METAvivor has put 100% of donations into its peer-reviewed research grant program.
Metastatic breast cancer (also known as Stage IV or advanced stage cancer) is the spread of breast cancer to other parts of the body -- most commonly to the bones, liver, lungs and/or brain. Approximately 30% of breast cancer patients metastasize, and 97 – 98% die as a result, with the average survival after diagnosis being two to three years. In the US, only 2-5% of all cancer research funds are dedicated to Stage IV cancer research – yet 99% of all breast cancer deaths are caused by a metastasis.
This is the eighth annual grant cycle funded by METAvivor, and this year, METAvivor is awarding grants from two award programs. Our newly established Young Investigator Award program is focused on funding grants for early career metastatic breast cancer researchers, while our standard awards program, now named the Translational Research Award, has changed to increase the amount of funding granted to $200,000 per grant for 2017.
In addition, we are pleased to announce the Kristin Keydel Endowment for Metastatic Breast Cancer Research Award and the Quinn-Davis Northwest Arkansas METSquerade Award. The grants named for donors and generous anonymous donors have helped METAvivor fund more exceptional research in 2017.
Beth Fairchild, President of METAvivor, said, "We are delighted to announce our latest research grant award recipients. Including this year’s grants, METAvivor has awarded a total of 45 grants totaling over $4,000,000 to career metastases researchers for treatments focusing on the already-metastasized patient."
"We hope that these grants, and the vital research that they fund, will move us closer to fulfilling our mission to transform metastatic breast cancer from a terminal disease into a chronic, manageable condition. We would like to thank our donors, research partners, sponsors and the metastatic breast cancer community for their ongoing support and commitment."
Below are the METAvivor 2017 grant recipients:
METAVIVOR YOUNG INVESTIGATOR AWARDS
Dr. Katherine Cook, Assistant Professor, Wake Forest University: "Dietary considerations effecting lung metastatic therapeutic responsiveness and co-morbidities."
Dr. Joshua Donaldson, Fellow in Oncology, Johns Hopkins University: "Resistance mechanisms to palbociclib in hormone positive metastatic breast cancer"
Dr. David Soto-Pantoja, Assistant Professor, Wake Forest School of Medicine: "Anti-CD47 Immunotherapy as a treatment for metastatic breast cancer"
The Kristin Keydel Endowment for Metastatic Breast Cancer Research presents: Dr. Gina Sizemore, Postdoctoral Fellow, Ohio State University: "Targeting novel tumor-stroma interactions in breast cancer brain metastases"
Dr. Rebecca Watters, Research Assistant Professor, University of Pittsburgh: "Discovery of Clinically Actionable Genes in Breast Cancer Bone Metastases"
RESEARCH AWARDS
Dr. Diana Cittelly, Assistant Professor, University of Colorado: "Targeting BDNF/TrkB in brain metastases from young women with TNBC "
Dr. Michael Flister, Assistant Professor, Medical College of Wisconsin: "Personalized therapy for curing metastatic breast cancer"
Dr. Melanie Hayden-Gephart, Assistant Professor, Stanford University: "Halting the Progression of Breast Cancer Leptomeningeal Brain Metastases"
The Quinn-Davis Northwest Arkansas Metsquerade presents Dr. Cheryl Jorcyk, Director of Clinical/Translational Research, Boise State University: "High impact therapeutic for the elimination of breast cancer metastasis to bone"
Dr. James McIntyre, Research Professor of Radiology and Radiological Sciences, VUMC Nashville: "A Novel Self-Reporting Paclitaxel Prodrug witho...
(All Rights Reserved)